Lenalidomid Grindeks

Lenalidomide, the active ingredient in Lenalidomid Grindeks, is an immunomodulatory agent presented as an oral dosage form for systemic use. It is employed in the treatment of certain blood cancers, notably multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomid Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomid Grindeks is used within the antineoplastic therapeutic class to target malignant plasma‑cell and myeloid disorders. - Multiple myeloma: improves progression‑free and overall survival in patients with relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and may achieve cytogenetic remission. - Relapsed or refractory multiple myeloma: provides an additional line of therapy after prior treatments have failed.

Lenalidomid Grindeks may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Nausea: sensation of unease and urge to vomit. - Rash: skin irritation or redness. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers. - Severe neutropenia: markedly low neutrophil levels requiring medical intervention. - Hepatic failure: significant liver dysfunction. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Blood count monitoring: perform regular CBC to detect cytopenias. - Renal function assessment: adjust therapy if creatinine clearance is reduced. - Pregnancy risk: avoid use in pregnant women; enforce effective contraception. - Concomitant teratogenic drugs: do not co‑administer with agents known to cause birth defects. - Infection vigilance: educate patients to report signs of infection promptly. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomid Grindeks can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Immunosuppressants (e.g., cyclosporine): increased toxicity risk. - Live vaccines: risk of uncontrolled infection.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin): monitor for bleeding tendencies. - NSAIDs: assess gastrointestinal and renal safety. - Other CYP3A4 substrates (e.g., statins): watch for altered plasma concentrations. - Digoxin: potential for altered cardiac effects. - Hormonal contraceptives: efficacy may be reduced; consider alternative methods.